Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2012 2
2014 1
2015 1
2018 1
2019 3
2020 3
2021 6
2022 5
2023 1
2024 3
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Targeting TP53 Mutations in Myelodysplastic Syndromes.
Hunter AM, Sallman DA. Hunter AM, et al. Hematol Oncol Clin North Am. 2020 Apr;34(2):421-440. doi: 10.1016/j.hoc.2019.11.004. Epub 2019 Dec 12. Hematol Oncol Clin North Am. 2020. PMID: 32089220 Review.
Molecular genetics of MDS/MPN overlap syndromes.
Hunter AM, Padron E. Hunter AM, et al. Best Pract Res Clin Haematol. 2020 Sep;33(3):101195. doi: 10.1016/j.beha.2020.101195. Epub 2020 Jul 5. Best Pract Res Clin Haematol. 2020. PMID: 33038984 Review.
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.
Jabbour E, Oehler VG, Koller PB, Jamy O, Lomaia E, Hunter AM, Uspenskaya O, Samarina S, Mukherjee S, Cortes JE, Baer MR, Zherebtsova V, Shuvaev V, Turkina A, Davydkin I, Guo H, Chen Z, Fu T, Jiang L, Wang C, Wang H, Yang D, Zhai Y, Kantarjian H. Jabbour E, et al. Among authors: hunter am. JAMA Oncol. 2025 Jan 1;11(1):28-35. doi: 10.1001/jamaoncol.2024.5157. JAMA Oncol. 2025. PMID: 39570620 Clinical Trial.
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
You X, Liu F, Binder M, Vedder A, Lasho T, Wen Z, Gao X, Flietner E, Rajagopalan A, Zhou Y, Finke C, Mangaonkar A, Liao R, Kong G, Ranheim EA, Droin N, Hunter AM, Nikolaev S, Balasis M, Abdel-Wahab O, Levine RL, Will B, Nadiminti KVG, Yang D, Geissler K, Solary E, Xu W, Padron E, Patnaik MM, Zhang J. You X, et al. Among authors: hunter am. Blood. 2022 Feb 17;139(7):1066-1079. doi: 10.1182/blood.2021012519. Blood. 2022. PMID: 34699595 Free PMC article.
27 results